CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing EYLUXVI® to the reference product Eylea®Upon approval, EYLUXVI® will...
The opinion will now be referred to the European Commission for final regulatory decision on donanemab
INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and...
82km of drilling and $9M invested in resource development and exploration in Q4, FY25
PERTH, Western Australia, July 23, 2025 /CNW/ - Westgold Resources Limited...
BMM: TSX-V
VANCOUVER, BC, July 22, 2025 /CNW/ - Black Mammoth Metals Corporation (TSXV: BMM) (OTC: LQRCF) ("Black Mammoth" or the "Company") is pleased to report assay...
Not for distribution to United States newswire services or for dissemination in the United States
VANCOUVER, BC, July 21, 2025 /CNW/ - Applied Graphite Technologies...
Solid low-cost production profile from year one via a phased mine plan:Phase 1: Low Initial capital cost of $155 million, builds average annual gold...
Solid low-cost production profile from year one via a phased mine plan:Phase 1: Low Initial capital cost of $155 million, builds average annual gold...
VANCOUVER, BC, July 21, 2025 /PRNewswire/ - Kootenay Silver Inc. ("Kootenay" or the "Company") (TSXV: KTN) (OTCQX: KOOYF) is pleased to announce drill crews...
VANCOUVER, BC, July 21, 2025 /CNW/ - Kootenay Silver Inc. ("Kootenay" or the "Company") (TSXV: KTN) (OTCQX: KOOYF) is pleased to announce drill crews...
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
Intersects Ginguro-Banded Quartz Veins
OTTAWA, ON, July 18, 2025 /CNW/ - Northern Shield Resources Inc. ("Northern Shield" or the "Company") (TSXV: NRN) is pleased to...